• News
  • SAN DIEGO
  • BioTech

Mallinckrodt to acquire Cadence Pharmaceuticals for $1.21B

The health care products company Mallinckrodt is buying San Diego-based Cadence Pharmaceuticals (Nasdaq: CADX) for about $1.21 billion in a bid to strengthen its specialty drugs unit.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Cadence Pharmaceuticals Inc.

Company Website

12481 High Bluff Dr. Ste., 200
San Diego, CA 92130

Subscribe Today!